Litcius/Paper detail

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Evanthia T. Roussos Torres, Won Jin Ho, Ludmila Danilova, Joseph A. Tandurella, James M. Leatherman, Christine I. Rafie, Chenguang Wang, Adam Brufsky, Patricia LoRusso, Vincent Chung, Yuan Yuan, Melinda Downs, Ashley O’Connor, Sarah M. Shin, Alexei Hernandez, Elizabeth L. Engle, Richard Piekarz, Howard Streicher, Zahra Talebi, Michelle A. Rudek, Qingfeng Zhu, Robert A. Anders, Ashley Cimino‐Mathews, Elana J. Fertig, Elizabeth M. Jaffee, Vered Stearns, Roisín M. Connolly

2024Nature Cancer47 citationsDOIOpen Access PDF

Topics & Concepts

IpilimumabNivolumabMedicineBreast cancerInternal medicineOncologyTriple-negative breast cancerCancerClinical endpointClinical trialImmunotherapyCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial | Litcius